TY - JOUR T1 - Impact of Adjuvant Pelvic Radiotherapy in Stage I Uterine Sarcoma JF - Anticancer Research JO - Anticancer Res SP - 365 LP - 370 VL - 35 IS - 1 AU - WILLIAM J. MAGNUSON AU - DANIEL G. PETEREIT AU - BETHANY M. ANDERSON AU - HEATHER M. GEYE AU - KRISTIN A. BRADLEY Y1 - 2015/01/01 UR - http://ar.iiarjournals.org/content/35/1/365.abstract N2 - Background/Aim: The optimal adjuvant therapy for stage I uterine sarcoma remains unresolved and may consist of radiotherapy (RT), chemotherapy, hormonal therapy or observation. We analyzed the impact of adjuvant pelvic RT on overall survival (OS), cause-specific survival (CSS), disease-free survival (DFS), pelvic control (PC) and patterns of failure. Patients and Methods: A retrospective analysis of 157 patients with International Federation of Gynecology and Obstetrics FIGO stage I uterine sarcoma was performed. RT was given postoperatively to a dose of 45-51 Gy in 28-30 fractions. Results: The 5-year OS, CSS, DFS and PC was 58%, 62%, 47% and 72%, respectively. Adjuvant RT significantly improved PC (85% for RT group vs. 64% for non-RT group; p=0.02) but did not impact OS, CSS or DFS. Conclusion: The addition of adjuvant pelvic RT significantly improved PC for patients with stage I uterine sarcoma. As systemic therapies continue to improve, optimal locoregional control may result in improved patient outcomes. ER -